Illustrative image.
Prempro
Conjugated Estrogens
$105.00
0.3/1.5mg · 84 tablets · 3 months supply
GenericGeneric medicine
$35.00 per month
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$420a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningCardiovascular disorders, breast cancer, endometrial cancer and probable dementia
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.
Breast Cancer
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen-Alone Therapy
Endometrial Cancer
The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo.
The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI)
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
About Prempro
Overview
Prempro is a prescription tablet containing conjugated estrogens and medroxyprogesterone acetate, an estrogen–progestin combination. It is used in women with a uterus to treat moderate to severe menopausal hot flashes and thinning of vulvar and vaginal tissues. It is also used to prevent osteoporosis after menopause. The estrogen acts on hormone receptors in the body, while the progestin helps reduce estrogen’s effects on the lining of the uterus.
What it treats
- Moderate to severe hot flashes due to menopause in women with a uterus. - Moderate to severe thinning and dryness of vulvar and vaginal tissues due to menopause in women with a uterus. - Prevention of osteoporosis after menopause in women with a uterus.
Safety information
Side effects
Common side effects include abdominal pain, weakness, back pain, headache, gas, nausea, depression, itching, breast pain, painful periods and vaginal discharge. Serious risks include cardiovascular disorders, cancers and an increased risk of gallbladder disease. Contact a doctor if you develop symptoms of a serious reaction. Stop taking Prempro and seek medical advice immediately if you experience loss of vision, jaundice caused by blocked bile flow, severely elevated blood calcium or severely elevated triglycerides (a type of blood fat).
FDA boxed warning
Cardiovascular disorders, breast cancer, endometrial cancer and probable dementia
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.
Breast Cancer
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen-Alone Therapy
Endometrial Cancer
The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo.
The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI)
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take Prempro if you have unexplained abnormal genital bleeding; known, suspected or past breast cancer; a known or suspected estrogen-dependent tumour; current or past blood clots in the deep veins or lungs; or current or past arterial blood clots, such as a stroke or heart attack. It must also not be used if you have liver disease or impaired liver function, protein C, protein S or antithrombin deficiency, another known disorder that increases blood clotting, or if you are pregnant or may be pregnant. Do not take it if you have had anaphylaxis or angioedema, a serious swelling reaction, to Prempro. Estrogens increase the risk of gallbladder disease. Treatment should be stopped if severely elevated blood calcium, loss of vision, severely elevated blood triglycerides or jaundice caused by impaired bile flow occurs. Women taking thyroid replacement therapy need thyroid function monitoring. Estrogen can reduce the quantity and quality of breast milk in breastfeeding women. An increased risk of probable dementia was reported in women over 65 in the Women’s Health Initiative Memory studies.
Interactions
Medicines that increase or block the activity of the enzyme CYP3A4 may affect how the body processes the estrogen in Prempro. Aminoglutethimide may significantly reduce the amount of medroxyprogesterone acetate available to the body. Tell your doctor if you take these medicines.
Using Prempro
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label PREMPRO (CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE) TABLET, SUGAR COATED [A-S MEDICATION SOLUTIONS] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Premarin
Conjugated Estrogens
Tablets · from 84 per pack
Same active ingredient as Prempro
Brand and generic from $17.00
Premarin Vaginal Cream
Conjugated Estrogens
By Pfizer
Tube · from 1 per pack
Same active ingredient as Prempro
Brand $95.00
Increlex
Mecasermin
By Ipsen
Syringes · from 1 per pack
Also for hormone replacement therapy
Brand $1,250.00
Natpara
Parathyroid Hormone (1‑84), Recombinant Human Parathyroid Hormone
By NPS Pharmaceuticals
Pack · from 1 per pack
Also for hormone replacement therapy
Brand from $12,435.00